Advertisement
Advertisement
U.S. markets open in 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
16.70+0.04 (+0.24%)
At close: 04:00PM EDT
16.99 +0.29 (+1.74%)
Pre-Market: 08:56AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close16.66
Open17.00
Bid16.45 x 1300
Ask17.00 x 1400
Day's Range16.63 - 17.20
52 Week Range10.81 - 20.50
Volume797,260
Avg. Volume796,829
Market Cap497.627M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ICPT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intercept Pharmaceuticals, Inc.
    Analyst Report: Intercept Pharmaceuticals, Inc.Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
    Rating
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more
Advertisement
Advertisement